Mount Yale Investment Advisors LLC Cuts Stake in GSK plc (NYSE:GSK)

Mount Yale Investment Advisors LLC trimmed its holdings in GSK plc (NYSE:GSK - Free Report) by 68.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,930 shares of the pharmaceutical company's stock after selling 23,951 shares during the period. Mount Yale Investment Advisors LLC's holdings in GSK were worth $370,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC lifted its position in shares of GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC lifted its stake in GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock valued at $759,425,000 after purchasing an additional 870,449 shares during the last quarter. Clifford Capital Partners LLC grew its holdings in GSK by 14.3% during the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company's stock valued at $16,747,000 after purchasing an additional 51,378 shares during the period. Cerity Partners LLC lifted its position in shares of GSK by 61.8% during the 3rd quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company's stock valued at $17,728,000 after buying an additional 165,556 shares during the last quarter. Finally, Natixis Advisors LLC lifted its position in shares of GSK by 20.0% during the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company's stock valued at $20,460,000 after buying an additional 83,433 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

GSK Price Performance

NYSE:GSK traded up $0.29 during trading hours on Thursday, hitting $35.35. The stock had a trading volume of 5,020,400 shares, compared to its average volume of 4,141,552. The firm has a market capitalization of $73.27 billion, a price-to-earnings ratio of 22.96, a P/E/G ratio of 1.31 and a beta of 0.63. GSK plc has a one year low of $31.72 and a one year high of $45.92. The company has a 50 day simple moving average of $34.01 and a two-hundred day simple moving average of $37.73. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

Wall Street Analyst Weigh In

GSK has been the topic of a number of research reports. Guggenheim cut GSK from a "buy" rating to a "neutral" rating in a research note on Thursday, October 31st. StockNews.com lowered shares of GSK from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, January 21st. Jefferies Financial Group downgraded shares of GSK from a "buy" rating to a "hold" rating and cut their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft cut shares of GSK from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Six investment analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.